

psyomics

**The first integrated
Digital & Biomarker
Platform for lifetime
behavioral health service**

The industry leading digital platform that onboards, clinically assesses & diagnoses for all mental health conditions, leveraged by our proprietary world first biomarker for Bipolar 1 disorder

As the demand for mental health services continues to rise, healthcare systems worldwide face significant challenges. Independent evaluation across a population of three million adults in the UK demonstrated that Psyomics digital platform streamlines clinical assessments reducing administrative time, reaching diagnostics conclusions faster and reducing time to treatment, whilst significantly improving member engagement. This case study demonstrates evidence for Psyomics' ability to deliver precision mental health care in the US.

The Providers

Behavioral Health Providers face common issues across mental health services:



Increasing Demand:

In the UK over 1.4 million people are currently waiting for NHS-funded mental health care.



Capacity Shortages:

Workforce challenges hinder the ability to meet this growing demand.



Clinical Variation:

Unwarranted variation in triage and assessment processes affects member outcomes and resource allocation.

These challenges mirror the US where members want quicker access to the right help, providers require assurance that members are receiving a standardization of care, and clinical and administrative burden is minimized.

Supporting Mental Health Services Worldwide




The Solution: Psyomics Platform

Our platform is a digital mental health platform that standardizes the triage and assessment processes, facilitating more personalized and efficient care. Officially launched to the market in September 2023, it enables clinicians to collect comprehensive member information before initial assessments, enhancing the quality of care, including reimbursement opportunities.

Implementation

- 1 **Referral Processing:** New referrals are processed through the Health System's Electronic Medical Record (EMR).
- 2 **Adaptive Assessment questionnaire:** Non-urgent cases are directed to Psyomics, which sends a URL via SMS for members to complete an adaptive assessment questionnaire.
- 2 **Integration:** Personalized member reports are generated using the data collected through the questionnaire and integrated into the EMR for clinician review.



Benefits of Psyomics Platform



For Clinicians

- Reduce the administrative burden
- Free up clinical time
- Practice at the top of the license
- More information to make triage, assessment, pathway and treatment decisions
- More engaged members
- Anticipate service demand



For Members


- Enhance members communication whilst reducing repetition
- Meet members where they are
- Encourage member choice
- Ensure equity of access
- Reduce time to treatment
- Right pathway first time



Health & Care Systems


- Deliver cost savings
- Reduce variation in care
- Improve member flow
- Enhance safety
- Data driven care management
- Reduce system complexity

Interim Results




Completion Rate

On average 75% of members completed the assessment, rising to >95% for private payers.



Clinician Alignment

91% of clinicians found Psyomics Platform reports aligned with their clinical evaluations.




Satisfaction

75% of members reported improved satisfaction with the process, compared to traditional routes to treatment.



Efficiency

Introduction of Psyomic's digital assessment in one NHS Trust led to zero repeat assessments.



Appropriate

89% of patients felt it covered all or most of their issues.

// Psyomics Platform helped streamline my assessments.

Community Psychiatric Nurse

// It saved me time on the assessment. I used the information to refer to in the assessment.

Consultant Psychiatrist

//

The experience is simple, easy to use and supportive.

Member

//

I'm very grateful this exists.

Member

5.9x

Return on investment in Year 1 on operational efficiencies alone

Transforming Bipolar Diagnosis with the Psyomics Biomarker Panel

Psyomics is pioneering the future of psychiatric diagnostics by combining cutting-edge metabolomic science with digital mental health data. Our **biomarker panel for Bipolar I Disorder** is designed to support clinical decision-making and early diagnosis.

Bipolar affects over 4% of the world's population with 56% of sufferers in the UK still waiting for a diagnosis. Global times to diagnosis vary from 6-12 years, with many individuals first seeking help during depressive episodes, masking their history of mania or hypomania. Resulting in inaccurate diagnosis of Major Depressive Disorder (MDD) between 20.8-61.5% of the time, delaying effective treatment which sees 1 in 3 attempting suicide.

Our Innovation: Biomarker combined with Psyomics Digital Questionnaire

Developed with researchers at the University of Cambridge under Professor Sabine Bahn, the **multi-biomarker panel** that analyses dried blood spots through mass spectrometry, is combined with rich member-reported data from the **Psyomics Platform***. This unique approach to combining biological and digital markers leads to unparalleled diagnostic accuracy AUROC 0.96, whilst deliverable at scale.

*The platform captures context-rich clinical information, including validated mental health questionnaires, suicidality indicators, and social determinants of health—directly from service users.

Real-World Impact Potential

The combined biomarker and Psyomics Platform will:

- Enhance early identification of bipolar disorder
- Reduce misdiagnosis and incorrect treatment for depression
- Support clinicians in making confident, timely decisions
- Accelerates appropriate care pathways

We are actively engaging global partners for **multi-site clinical evaluations** to bring this technology into frontline mental health care.

For more information please contact Melinda.Rees@psyomics.com or Rupert.Hipwell@psyomics.com.

Introducing the Leadership Team



Melinda Rees
CEO



Rupert Hipwell
Chief Commercial Officer



Francisco Egana
Chief Financial Officer



Chloe Dowson
Chief Operating Officer



Alex Nancekievill
Chief Technology Officer

psyomics



Follow us to be the first to hear what's next:
<https://www.linkedin.com/company/psyomics/>

www.psyomics.com | melinda.rees@psyomics.com